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Edited by Lukas HuberAbstract Lung cancer is the leading cause of cancer death.
However, the mechanism of lung cancer relapse and metastasis
has been poorly elucidated. Recent researches have addressed
the role of MicroRNAs (miRNAs) in mediating tumor metasta-
sis. In the present study, we identiﬁed microRNA-183 (miR-183)
as a potential metastasis-inhibitor. Expression level of miR-183
was reversely correlated with the metastatic potential of lung
cancer cells. Furthermore, over-expression of miR-183 inhibited
migration and invasion of lung cancer cells. Mechanistically, we
identiﬁed VIL2-coding-protein Ezrin as a bona ﬁde target of
miR-183. We also found that miR-183 could regulate the expres-
sion of other genes involved in migration and invasion. Taken to-
gether, our ﬁndings demonstrated a new role and regulatory
mechanism of miR-183 in controlling cancer metastasis.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Lung neoplasm1. Introduction
Lung cancer, the leading cause of cancer deaths, has the
most rapidly increasing incidence rate in the developed country
as well as in China [1,2]. Clinical data have showed that most
lung cancer patients eventually suﬀered relapse and/or metas-
tasis after complete excision of the cancer, even if they were
at stage IA [3]. Despite the great progresses that has been made
in recent decades, the mechanism of lung cancer relapse and
metastasis is not fully understood.
MiRNAs are a class of small, non-coding RNA that play
important roles in various biological processes [4]. Bioinfor-
matic methods predicted that in approximately one-third of
all mammalian genes, especially those in down-stream of var-
ious signal transduction pathway, were targeted by miRNAs
[5,6]. Interestingly, accumulating evidence has implicated miR-
NAs in human cancer. Calin et al. revealed that 98 of 186 of
miRNA genes located in cancer-associated genomic regions
or in fragile sites and that down-regulation of miR-15 and
miR-16 was frequently found in chronic lymphocytic leukemia
[7,8]. Additionally, altered expression of the let-7 and miR-155
in lung cancer correlated with the survival of patients [9,10].
More recent studies in both in vitro and in vivo demonstrated*Corresponding author.
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cancer [11]. In addition, miR-200c has been shown to inﬂuence
E-cadherin expression and epithelial-to-mesenchymal transi-
tion, an essential early step in tumor metastasis [12]. However,
the role of miRNAs in mediating tumor metastasis has been
only recently investigated and still remains largely elusive.
In this study, we investigated the potential role of miRNA in
invasion and metastasis of lung cancer. Through a screen with
miRNA array, we identiﬁed miR-183 as a regulator of lung
cancer metastasis. First, expression of miR-183 was found to
be reversely correlated with the metastatic potential of lung
cancer cells. In addition, ectopic expression of miR-183 in
highly metastatic cells could inhibit cell migration and inva-
sion. Consistent with its cellular function, miR-183 regulated
the expression of many migration and invasion-related genes,
including Ezrin, which has a role in controlling actin cytoskel-
eton, cell adhesion and motility. This has been well established.
Together, our results strongly suggest that there is an impor-
tant regulatory role of miR-183 in lung cancer metastasis,
implying that it might be a useful diagnostic and prognostic
marker of lung cancer.2. Materials and methods
2.1. Cell culture
Paired high-metastatic human pulmonary giant cell carcinoma cell
801D, and low-metastatic human pulmonary giant cell carcinoma cell
95C were kindly provided by Professor Zhou Jianying (The 1st Aﬃli-
ated Hospital, Medicine School, Zhejiang University, China) and
grown in RPMI medium 1640 (Invitrogen, Carlsbad, CA) with 10%
fetal bovine serum (Shanghai Sangon Biological Engineering
Technology and Services Co., Ltd, Shanghai, China).
2.2. Isolation of total RNA
RNA was extracted by Trizol reagent (Invitrogen) as standard
method.
2.3. MiRNA microarray
Small RNA separating, quality control, labeling, hybridization and
scanning were performed by LC Sciences (Houston, TX, USA) using
miRHuman_10.0_070802 miRNA array chip, based on Sanger miR-
Base Release 10.0. Preliminary statistical analysis was performed by
LC sciences on raw data normalized by Locally-weighted Regression
(LOWESS) method on the background-subtracted data. Then, Stu-
dents t test was performed to identify the diﬀerent miRNA expression.
MiRNAs with P < 0.01 was considered as having signiﬁcant diﬀerence
between 801D and 95C.
2.4. RT-PCR
MiR-183, VIL2, KRTAP3-2, and RUNX1T1 mRNA expression
was measured by RT-PCR (details shown in Supplementary data).ation of European Biochemical Societies.
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We used the Transwell Insert (24-well Insert; pore size, 8 lm;
Corning, USA) and wound healing experiment to explore the eﬀect
of miR-183 on migration and invasion of 801D cells (details shown
in Supplementary data).
2.6. Growth inhibition and apoptosis test
VybrantMTT Cell Proliferation Assay Kit (Invitrogen) and annex-
in V-FITC apoptosis detection kit (B.D. Biosciences Pharmingen, San
Jose, CA USA) were employed to analyze cell growth and apoptosis
respectively (details shown in Supplementary data).
2.7. Bioinformatics analysis
Three programs, PicTar, miRanda, and TargetScan [13–15], were
used to predict the targets of miR-183.
2.8. Western blot
Ezrin protein was analyzed by Western blot using Ezrin Rabbit
Monoclonal Antibody (Epitomics Inc., USA) (details shown inSupple-
mentary data).
2.9. Plasmids construction and luciferase activities analysis
In order to construct plasmid pGL3-VIL2 3 0 un-translated region
(UTR) containing the binding site of miR-183, the following primers
were used to amplify and clone the 3 0 UTR of VIL2 gene into the
pGL3-control vector (Promega) according to manufacturers instruc-
tions: forward 5 0 ATCGATGGTACCATGCTGGCCTGTGT
GATAC30; reverse 5 0 CCGGGCAGATCTGAGCTCATTTCGAA-
TACAGAAC 3 0. Primers synthesizing and sequencing were fulﬁlled
by Shanghai Sangon Biological Engineering Technology and Services
Co. Ltd.
Forty-eight hours after transfection, luciferase activities were mea-
sured in Victor 1420 Multilabel Counter (Wallac, Finland) using Lucif-
erase Assay System (Promega) according to the manufacturers
protocol.
2.10. GeneChip mRNA array and Gene ontology (GO) analysis
Aﬀymetrix U133 plus 2 GeneChip (Aﬀymetrix, Santa Clara, CA,
USA) was used to explore the biological role of miR-183. 801D cells
un-treated or transfected with miR-183 or negative control were har-
vested 36 h post-transfection. RNA isolating, quality control, labeling,
hybridization, scanning, and data processing were performed by Gene-
times Technology Inc. (Shanghai, China). Genes which fulﬁlled the
cut-oﬀ criteria of a P value <0.05 and a linear fold change P 2 between
groups were considered as having signiﬁcant diﬀerences. GO analysis
was performed using the GO-annotations downloaded from http://
geneontology.org/.
2.11. Transfection
For miR-183 over-expression, 801D cells were transfected with the
Pre-miRTM miRNA Precursor of miR-183 (Ambion Inc., USA) at
30 nmol/L ﬁnal concentration using NeoFx (Ambion Inc.) and
OPTI-MEM I Reduced-Serum Medium (Invitrogen). Eﬃciency of
over-expression of miR-183 was measured by RT-PCR. Cy3-labeled
Pre-miR Negative Control#1 (Ambion Inc.) was used as negative
control for miR-183 over-expression.
TransFast Transfection Reagent (Promega, Madison, USA) was
used to transfect pGL3 plasmid with or without VIL2 3 0 UTR into
801D cells according to the manufacturers protocol.
2.12. Statistical methods
Diﬀerences between groups were compared using Pearsons chi-
square test for qualitative variables and Students t-test for continuous
variables. P values <0.05 was considered signiﬁcant.0.00
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Fig. 1. MiR-183 was lowly expressed in 801D cells. RNA was isolated
from diﬀerent human pulmonary giant cell carcinoma cells, and miR-
183 expression was analyzed by RT-PCR. The results represent the
relative miR-183 level to un-treated 801D cells.3. Results
3.1. Reduced expression of miR-183 in 801D cell
To study the potential role of miRNA in lung cancer metas-
tasis, we used the miRHuman_10.0_070802 miRNA array,which contained 711 probes, to scan miRNAs that were diﬀer-
entially expressed between paired high or low metastatic pul-
monary giant cell cancer cells. In this study, 801D and 95C
cell lines were chosen because they were originated from the
same maternal cell line but displayed very dramatic diﬀerences
in metastatic ability. Among 711 miRNAs screened, 92 miR-
NAs exhibited signiﬁcantly diﬀerent expression level between
801D and 95C cells (Supplementary Table 1). Of these poten-
tial candidates, we focused on miR-183 because its one of the
most obviously altered miRNAs and was deregulated in colo-
rectal cancer with unclear function [16]. Consistent with the ar-
ray results, RT-PCR further validated that miR-183
expression level in 801D was less than half of that in 95C
(Fig. 1). Together, it suggested that expression level of miR-
183 was inversely related to lung cancer metastasis.
3.2. MiR-183 repressed cell migration and invasion in vitro
Cell migration and invasion are two essential processes in
cancer metastasis. In accord with their metastatic potential,
801D displayed signiﬁcantly higher migratory and invasive
capability in vitro (data not shown). Thus, to explore the po-
tential role of miR-183 in lung cancer metastasis, we ﬁrst
examined the consequence in cell motility and invasive capabil-
ity after ectopic expression of miR-183 in 801D cells which had
very low level of endogenous miR-183. Transwell Insert results
showed that additional miR-183 signiﬁcantly inhibited chemo-
taxis of 801D cells (Fig. 2a). We then assayed the polarized
migration of cells using scratch-wound model. As shown in
Table 1 and Fig. 2b, cells transfected with miR-183 closed
the scratch-wounds more slowly than cells un-treated or trans-
fected with negative control. To examine the invasion capabil-
ity, transfected or un-transfected 801D cells were plated on top
of a layer of ECM extracted from mouse sarcoma. Cells that
penetrated this barrier and reach the other side of the Trans-
well were recorded after 48 h of incubation. Consistent with
the migration results, expression of miR-183 in 801D cells sig-
niﬁcantly inhibited their invasion (Fig. 2c). These diﬀerences
appeared to be rooted in migration and invasion per se rather
than defects in cell proliferation or cell death, as our MTT
analysis found that miR-183 did not signiﬁcantly inﬂuence
viability of 801D cells (Fig. 3a), and expression of miR-183
did not result in obvious apoptosis in 801D cells (Fig. 3b).
Together, our results demonstrated that miR-183 played an
inhibitory role in 801D cells migration and invasion in vitro.
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Fig. 2. Transwell Insert and wound healing assay showed that miR-183 negatively regulated cell migration and invasion in vitro. (a) After initial
equilibrium, un-transfected or transfected with miR-183 or negative control 801D cells suspended in fresh medium without fetal bovine serum were
added to the Insert. Forty-eight hours after seeding, the cells on the lower surface of the Insert were ﬁxed and stained. Six visual ﬁeld of each Insert
were randomly counted under a microscope. The migratory cell number of 801D transfected with miR-183 was signiﬁcantly less than that of 801D
cells transfected with negative control. (b) Conﬂuent cell monolayers were wounded with a pipette tip. Wound closure was monitored by microscopy
at the indicated times. (c) For invasion assay, the Inserts were coated with ECM and then repeated as migration assay. The invasive cell number of
801D transfected with miR-183 was also signiﬁcantly less than that of 801D cells transfected with negative control. Magniﬁcation in a, c, ·200, in c,
·100. (*) = P < 0.005 compared to negative control transfected 801D cells.
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Table 1
MiR-183 over-expression signiﬁcantly decreased wound healing capacity of 801D cells when compared with both un-treated 801D and 801D
transfected with negative control. Data were described as closed width/scratched width (%, means ± S.D.).
Time point (hour) 0 6 12 24 36 48
801D 0 ± 0 14.15 ± 0.78 32.87 ± 1.74 85.97 ± 3.98 100 ± 0 100 ± 0
801D with miR-183 0 ± 0 13.48 ± 0.71 30.62 ± 1.37 67.30 ± 2.56* 76.50 ± 2.59* 100 ± 0
801D with negative control 0 ± 0 13.50 ± 1.58 31.57 ± 1.38 86.18 ± 3.97 99.78 ± 0.57 100 ± 0
*P < 0.05, when compared with both 801D with negative control and 801D.
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Fig. 3. MiR-183 had little eﬀect on cell viability and apoptosis. (a)
Cells were seeded in 96-well plates. MTT was added to each well for
3 h at 37 C and then replaced by DMSO. Absorbance was read at
570 nmol/L. The data were presented as percentage of growth relative
to that of un-treated 801D cells. (b) Seventy-two hours after
transfection, the cells were harvested and stained with FITC-conju-
gated anti-annexin V antibody and PI. Stained cells were then
quantiﬁed by FACSCalibur ﬂow cytometry.
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Fig. 4. MiR-183 directly suppressed VIL2. (a) Western blot showed
that Ezrin expression was signiﬁcantly higher in 801D cells than in 95C
cells, and that, after transfection with miR-183, it was nearly
disappeared. In contrast, negative control had little eﬀect on Ezrin
expression in 801D cells. b-Actin was used as positive control. (b)
Luciferase activity measurement showed that when compared with co-
transfection with pGL3-VIL2 and negative control, co-transfection
with pGL3-VIL2 and miR-183 resulted in 2–3 fold decrease in 801D
cells. In contrast, the luciferase activities of co-transfection with pGL3
vector and miR-183, co-transfection with pGL3 vector and negative
control, and transfection with pGL3-VIL2 alone were similar to that of
co-transfection with pGL3-VIL2 and negative control. The data were
normalized to an internal control and each bar represented the mean
value ± S.D. from three independent experiments. Empty pGL3-
control vector was used as positive control. (*) = P < 0.0001 compared
to negative control transfected samples.
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To further investigate the mechanism of miR-183 in lung
cancer metastasis, we employed in silico analysis using three
miRNA target prediction programs (TargetScan, PicTar and
miRanda) [13–15]. Notably, all these databases predicted that
VIL2, which contained the binding site of miR-183 in its 3 0
UTR, could be regulated by miR-183 (Supplementary
Fig. 1). Interestingly, previous works have demonstrated that
expression of Ezrin expression was associated with tumor
invasion and metastasis [17]. So, it is tempting to speculate that
up-regulation of miR-183 might impair cell migration and
invasion via down-regulation of Ezrin.
To test this hypothesis, we ﬁrst examined Ezrin expression
by Western blot. Our data showed that Ezrin expressed at a
signiﬁcantly higher level in 801D than in 95C (Fig. 4a). Inter-
estingly, after transfection with miR-183, Ezrin expression in
801D cell was almost abolished. In contrast, negative control
RNA had little or none eﬀect on Ezrin expression (Fig. 4a).
However, RT-PCR showed that miR-183 expression could
not decrease mRNA level of VIL2 (data not shown), suggest-
ing that miR-183 regulated Ezrin expression at a post-tran-
scriptional level.To further conﬁrm VIL2 as a direct target of miR-183, the 3 0
UTR of VIL2, containing binding site of miR-183, was fused
with a luciferase reporter gene, and the resultant luciferase
activities were examined. As expected, over-expression of
miR-183 resulted in signiﬁcant decrease in the luciferase activ-
ity (Fig. 4b). Thus, our data strongly suggested that VIL2 was
a direct target of miR-183.
3.4. Microarray analysis revealed metastasis – associated genes
whose expression changed in the presence of excess miR-183
To further explore the role of miR-183 in tumor metastasis,
we performed microarray analysis using Aﬀymetrix U133 plus
G. Wang et al. / FEBS Letters 582 (2008) 3663–3668 36672 GeneChips to compare gene expression proﬁles among un-
treated 801D cells and 801D cells transfected with ectopic
expression of either miR-183 or negative control. Previous
study demonstrated that miRNAs repression happened in a
transient manner. For instance, CDK6, a conﬁrmed target of
let-7, was repressed at 36 h by let-7 but recovered to normal le-
vel by 72 h [18]. Thus, we harvested cells at 36 h post-transfec-
tion. With the criterion of a P value <0.05 and at least two-fold
changes of expression level, we identiﬁed 424 (258 repressed
and 166 up-regulated) genes that were diﬀerentially expressed
(data not shown).
Genes, whose expression level was signiﬁcantly altered,
were grouped by their assigned biological functions using
the GO database. Interestingly, we found that among the
424 miR-183-responding genes, 9.69% (25/258) of down-regu-
lated genes and 7.23% (12/166) of up-regulated genes were
functioning in cell adhesion, migration, invasion, and/or
metastasis (Supplementary Table 2), including: CCL5, which
enhanced motility, invasion, and metastasis of breast cancer
cells through the chemokine receptor CCR5 [19]; CTHRC1,
which promoted melanoma cells migration and were aberrant
in human solid cancers [20]; CYR61[21] and various adhesion,
migration, invasion and angiogenesis–associated proteins.
RT-PCR veriﬁed that the mRNA level of KRTAP3-2and
RUNX1T1, the most obviously miR-183-responding genes,
could be down-regulated by over-expression of miR-183 (data
not shown), implying that miR-183 did regulate KRTAP3-
2and RUNX1T1 expression. Taken together, our results iden-
tiﬁed a group of metastasis-related genes whose expression
was regulated by miR-183, further supporting the potential
role of miR-183 in cancer metastasis.4. Discussion
The malignant progression of a tumor from benign to inva-
sive and metastatic is usually associated with a poor prognosis
for cancer patients. Tumor metastasis is a highly complex and
multistep process that includes altered cell adhesion, survival,
proteolysis, migration, lymph/angiogenesis, immune escape,
and homing on target organs. Cell motility and invasion are
essential features of the metastatic process, and the identiﬁca-
tion and characterization of molecules and their associated
pathways that control cell motility and invasion are critical
to our understanding of cancer metastasis. Recently, emerging
evidence has implicated miRNA in metastasis of human cancer
[11,12].
To identify potential miRNA involved in lung cancer metas-
tasis, we proﬁled miRNAs expression in paired high and low
metastatic cells originated from pulmonary giant cell cancer,
which is a speciﬁc type of lung cancer characterized by more
progressive clinical behavior. Interestingly, 92 of 711 assayed
miRNAs displayed signiﬁcantly diﬀerential expression levels
(Supplementary Table 1). Among these 92 potential targets,
some miRNAs have been previously demonstrated to be in-
volved in tumor [9,10,12]. Our miRNA proﬁling revealed a
2–3 fold decrease of miR-183 in highly metastatic lung cancer
cells versus non-metastatic counterparts derived from same
parental cell lines. We further utilized multiple cell-culture
based approaches to establish the inhibitory role of miR-183
in motility and invasion of lung cancer cell.Using both in-silico analysis and mRNA proﬁling, we iden-
tiﬁed several potential down-stream eﬀectors of miR183,
including Ezrin. Ezrin has been well recognized as a molecular
linker between actin cytoskeleton and plasma membrane, and
has been involved in the maintenance of cyto-morphology, cell
adhesion, and cell movement [17]. Thus, it is conceivable that
Ezrin might contribute to the regulation of metastasis by miR-
183. Interestingly, among 424 changed genes that we identiﬁed
by mRNA microarray, more than 30 genes were also involved
in metastasis. Their cellular functions encompass regulation of
extracellular matrix, cell adhesion, and cytoskeletal regulation.
Further study would be required to fully understand their role
in miR-183 regulation of lung cancer metastasis.
Interestingly, in addition to repress metastasis-promoting
genes expression, miR-183 also decreased metastasis-suppress-
ing genes mRNA level, such as WISP2, which decreased breast
tumor cells migration and invasion [22], and increased metas-
tasis-promoting genes expression, such as S100P, which pro-
moted metastasis of prostate cancer cell [23]. Its mechanism
and signiﬁcance remained to be further determined. Indeed,
the same miRNA, for example let-7, could act not only as
oncogene, but also as tumor suppress gene in diﬀerent cancer
cell [24,25].
Emerging evidence started to reveal the diverse and pro-
found role of various miRNA in regulating tumor metastasis.
Interestingly, in addition to miR-183, our proﬁling results also
showed changes in expression levels of many other miRNA,
such as miR-574 family & miR-29 family. Further study would
be required to fully understand the role of each individual
miRNA candidate in metastasis. When our paper was about
to be ﬁnished, there were other studies published, which iden-
tiﬁed miR-126, miR-335, miR-373, miR-520c, miRNA-200
family and miR-205 as tumor metastasis-associated miRNAs,
further supporting that miRNAs might be involved in tumor
metastasis [26–28].
In conclusion, our results identiﬁed miR-183 as a new
molecular target involved in lung cancer metastasis, and shed
mechanistic insight into its role in cell migration and invasion.
Our work might provide an important avenue for developing
new diagnostic and therapeutic targets for the treatment of
metastatic lung cancer.
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